New Research Offers an In-Depth Competitive Landscape Assessment of the Targeted Oncology Market Place.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c45675) has announced the addition of "Targeted Therapies in Oncology: A World Review "to their offering. The dogma DOGMA, civil law. This word is used in the first chapter, first section, of the second Novel, and signifies an ordinance of the senate. See also Dig. 27, 1, 6. for treatment of cancer has changed, with the cytotoxic drugs Cytotoxic drugs Drugs that function by destroying cells. Mentioned in: Antirheumatic Drugs used in chemotherapy regimes set to lose their dominance and be used alongside targeted therapies that are being developed with the aim of more specifically targeting cancer cells cells once believed to be peculiar to cancers, but now know to be epithelial cells differing in no respect from those found elsewhere in the body, and distinguished only by peculiarity of location and grouping. See also: Cancer . Research and analysis highlights -- In this comprehensive report covering targeted therapies in oncology, we have analyzed protein kinase inhibitors A protein kinase inhibitor is a type of enzyme inhibitor which specifically blocks the action of protein kinase. Kinase inhibitors such as dasatinib are sometimes used in the treatment of cancer. , anti-angiogenic and vascular targeting agents, immunostimulators, antibodies and vaccines in oncology. -- This extensive 410+ page report compiles and analyzes in parallel the progress concerning drug development and competitive situation in the mentioned key oncology targeted therapy areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors. -- The number of targeted therapy drugs has risen sharply, as have the number of targets. The fiercest competition in oncology targeted therapy is pointed out and how several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline. Scope of this report -- In-depth competitive landscape assessment of the targeted oncology market place; Including more than 300 drugs and pharmaceutical companies -- Thorough review of five major targeting strategies in oncology: Protein kinase inhibitors, Anti-angiogenic and vascular targeting agents, Immunostimulators, Antibodies and Vaccines -- Progress analysis of major cancer indications for respective targeting strategy, including players, drugs, clinical progress and pitfalls Key reasons to read this report -- Understand the clinical and strategic challenges to the commercialization of five major targeting strategies in oncology -- Assess opportunities and risks for the continued development of targeting agents in major cancer indications. -- Adopt knowledge from this analysis to drive strategic planning Strategic planning is an organization's process of defining its strategy, or direction, and making decisions on allocating its resources to pursue this strategy, including its capital and people. decisions in oncology drug development Topics Covered: -- Methodology -- Protein Kinase Inhibitors -- Anti-Angiogenesis & Vascular Targeting -- Immunotherapy Immunotherapy The treatment of cancer by improving the ability of a tumor-bearing individual (the host) to reject the tumor immunologically. There are molecules on the surface of tumor cells, and perhaps in their interior, that are recognized as different from in Oncology -- Competitive Landscape in Cancer Vaccines Cancer vaccines A treatment that uses the patient's immune system to attack cancer cells. Mentioned in: Pancreatic Cancer, Exocrine -- Antibody Deals on the Rise -- Tumor Antigens tumor antigen n. Any of several antigens present in tumors induced by certain types of adenoviruses and papovaviruses or in cells transformed in vitro by those viruses. Also called neoantigen, T antigen. -- Immunomodulators & Adjuvants in Cancer Vaccines -- Cancer Vaccine The term cancer vaccine is often used to describe a process whereby a person's immune system is coaxed into recognizing and destroying malignant cells without harming normal cells. Delivery -- New Approaches in Antibody Delivery and Design - The Next Generation -- Cancer Vaccines in Development: By Major Indications -- Antibodies in Clinical Development -- Company Index -- Drug Index Companies Mentioned: -- Novartis Deals -- AstraZeneca -- Pfizer -- GlaxoSmithKline For more information visit http://www.researchandmarkets.com/reports/c45675 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion